Tarsus Pharmaceuticals In...

50.04
0.07 (0.14%)
At close: Apr 25, 2025, 3:59 PM
50.00
-0.08%
After-hours: Apr 25, 2025, 04:38 PM EDT

Tarsus Pharmaceuticals Statistics

Share Statistics

Tarsus Pharmaceuticals has 41.61M shares outstanding. The number of shares has increased by 10.13% in one year.

Shares Outstanding 41.61M
Shares Change (YoY) 10.13%
Shares Change (QoQ) 8.84%
Owned by Institutions (%) 99.99%
Shares Floating 35.81M
Failed to Deliver (FTD) Shares 16.08K
FTD / Avg. Volume 2.54%

Short Selling Information

The latest short interest is 7.65M, so 18.58% of the outstanding shares have been sold short.

Short Interest 7.65M
Short % of Shares Out 18.58%
Short % of Float 19.2%
Short Ratio (days to cover) 10.48

Valuation Ratios

The PE ratio is -18.02 and the forward PE ratio is 40.31. Tarsus Pharmaceuticals's PEG ratio is 0.54.

PE Ratio -18.02
Forward PE 40.31
PS Ratio 11.38
Forward PS 2.1
PB Ratio 9.27
P/FCF Ratio -24.61
PEG Ratio 0.54
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Tarsus Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.42, with a Debt / Equity ratio of 0.32.

Current Ratio 4.42
Quick Ratio 4.39
Debt / Equity 0.32
Debt / EBITDA -0.68
Debt / FCF -0.86
Interest Coverage -16.19

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $566.42K
Profits Per Employee $-357.75K
Employee Count 323
Asset Turnover 0.49
Inventory Turnover 4.9

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by 56.18% in the last 52 weeks. The beta is 0.94, so Tarsus Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.94
52-Week Price Change 56.18%
50-Day Moving Average 47.87
200-Day Moving Average 41.86
Relative Strength Index (RSI) 54.69
Average Volume (20 Days) 633.56K

Income Statement

In the last 12 months, Tarsus Pharmaceuticals had revenue of 182.95M and earned -115.55M in profits. Earnings per share was -3.07.

Revenue 182.95M
Gross Profit 170.13M
Operating Income -120.57M
Net Income -115.55M
EBITDA -106.88M
EBIT -108.11M
Earnings Per Share (EPS) -3.07
Full Income Statement

Balance Sheet

The company has 94.82M in cash and 72.45M in debt, giving a net cash position of 22.37M.

Cash & Cash Equivalents 94.82M
Total Debt 72.45M
Net Cash 22.37M
Retained Earnings -360.21M
Total Assets 376.99M
Working Capital 276.09M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -83.03M and capital expenditures -1.57M, giving a free cash flow of -84.59M.

Operating Cash Flow -83.03M
Capital Expenditures -1.57M
Free Cash Flow -84.59M
FCF Per Share -2.25
Full Cash Flow Statement

Margins

Gross margin is 92.99%, with operating and profit margins of -65.9% and -63.16%.

Gross Margin 92.99%
Operating Margin -65.9%
Pretax Margin -63.16%
Profit Margin -63.16%
EBITDA Margin -58.42%
EBIT Margin -65.9%
FCF Margin -46.24%

Dividends & Yields

TARS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for TARS is $66, which is 31.9% higher than the current price. The consensus rating is "Buy".

Price Target $66
Price Target Difference 31.9%
Analyst Consensus Buy
Analyst Count 6
Stock Forecasts

Scores

Altman Z-Score 7.27
Piotroski F-Score 3